Join to access to all OVN content. Join for Free
Compliance 101-Most common issues and MSL-related gray areas
compliance in medical affairs MSL compliance FDA standards ethical collaboration professional development conferences

Compliance 101-Most common issues and MSL-related gray areas


Share This Article


Summary

In this episode, Jessica McLin and Melody Davis explore the intricacies of compliance and communication in medical affairs. Jessica shares her journey into entrepreneurship and discusses her work with Versant Learning Solutions. The conversation covers FDA standards, ethical collaboration with sales reps, and the importance of understanding company SOPs. They delve into strategies for navigating compliance gray areas and the role of training, especially in smaller companies. The episode also highlights the significance of professional development through conferences and the importance of leadership in enforcing compliance. Finally, they address key compliance rules and best practices for MSLs, including the Sunshine Act.

Today’s guests are Jessica McLin and Melody Davis of Versant Learning. We discuss MSL Compliance 101 and the most common issues and MSL-related gray areas.

In this episode we discuss:

  • Jessica and Melody intro
  • What Versant Learning does
  • Compliance and what people need to know
  • The most common gray areas to look out for
  • Where can an MSL find compliance information outside their current organization
  • The role of MSL Leadership in communicating compliance standards and how much of the effort lies on the MSL
  • The most important for the MSLs to keep in mind

Click for Source
compliance in medical affairs, MSL compliance, FDA standards, ethical collaboration, professional development conferences

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How Should Medical Affairs Engage on Social Media
Partner Avatar MSL Talk: Tom Caravela

How Should Medical Affairs Engage on Social Media

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Explore OVN